comparemela.com

Latest Breaking News On - Lactams - Page 3 : comparemela.com

Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer

PHILADELPHIA – Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research , a journal of the American Association for Cancer Research.

United-states
Philadelphia
Pennsylvania
American
Andrew-armstrong
Genentech-roche
Johns-hopkins-university
Urologic-cancers-at-duke-university
Novartis
Molecular-cancer-research
Pfizer
Astrazeneca

Alembic Pharmaceuticals gets USFDA nod for bipolar depression drug

Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Lurasidone Hydrochloride tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Alembic Pharmaceuticals said in a regulatory filing. Quoting IQVIA data, Alembic Pharma said Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg have an estimated market size of USD 3.7 billion for the twelve months ending December 2020.

Alembic-pharmaceuticals
Alembic-pharmaceuticals-on
Sunovion-pharmaceuticals-inc
Drug-administration
Lurasidone-hydrochloride
Sunovion-pharmaceuticals
Alembic-pharma
Lurasidone-hydrochloride-tablets
Chemical-compounds
Atypical-antipsychotics
Organic-compounds

Glenmark Pharmaceuticals receives USFDA approval for Tadalafil Tablets

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg, the generic version of Cialis1 Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, of Eli Lilly and Company. According to IQVIATM sales data for the 12 month period ending November 2020, the Cialis Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market2 achieved annual sales of approximately $125.5 million. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these

Eli-lilly
Glenmark-pharmaceuticals
United-states-food-drug-administration
United-states-food
Drug-administration
Tadalafil-tablets
Cialis-tablets
Capital-market
Drugs
Branches-of-biology
Lactams
Pde5-inhibitors

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.